Brenig Therapeutics Announces the Initiation of First-in-Human Clinical Trial of BT-267, a Best-in-Class LRRK2 Inhibitor for Parkinson's Disease
Brenig Therapeutics announced the initiation of the first-in-human clinical trial for BT-267, a best-in-class LRRK2 inhibitor developed as a potential disease-modifying treatment for idiopathic and ...
The Cool Down on MSN43m
Scientists achieve record-breaking efficiency with smooth and improved solar tech — here's how it could change the energy industry
By using a post-deposition in situ passivation strategy, the team at Spain's Institute of Photonic Sciences has been able to ...